What prompted the recall at Able Labs?

USA Today examines the strange case of Able Laboratories, the generic drug maker which pulled all of its drugs from the market in one of the biggest recalls ever to hit the business. But a month after the recall, after Able's stock has fallen 86%, little is known about what prompted the recall or what Able needs to do to fix the problem. Some of the most important unanswered questions lie with the FDA, which repeatedly inspected Able's facilities without raising any concerns.

- read this story from USA Today

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.